Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Account Payables: 2023-2025

Historic Change in Account Payables for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to -$1.2 million.

  • Contineum Therapeutics' Change in Account Payables fell 284.16% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$653,000, marking a year-over-year decrease of 573.19%. This contributed to the annual value of $1.1 million for FY2024, which is N/A change from last year.
  • Contineum Therapeutics' Change in Account Payables amounted to -$1.2 million in Q3 2025, which was up 25.73% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Change in Account Payables registered a high of $1.8 million during Q1 2025, and its lowest value of -$1.6 million during Q2 2025.
  • Its 3-year average for Change in Account Payables is $10,000, with a median of $170,000 in 2024.
  • Within the past 5 years, the most significant YoY rise in Contineum Therapeutics' Change in Account Payables was 2,720.00% (2025), while the steepest drop was 1,067.06% (2025).
  • Quarterly analysis of 3 years shows Contineum Therapeutics' Change in Account Payables stood at -$625,000 in 2023, then skyrocketed by 160.48% to $378,000 in 2024, then tumbled by 284.16% to -$1.2 million in 2025.
  • Its Change in Account Payables stands at -$1.2 million for Q3 2025, versus -$1.6 million for Q2 2025 and $1.8 million for Q1 2025.